Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell

Author(s): Shahzad Khan*, Syed S. Ahmad, Mohammad A. Kamal

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 21 , Issue 2 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus characterized by gradually failing heart with detrimental cardiac remodelings, such as fibrosis and diastolic and systolic dysfunction, which is not directly attributable to coronary artery disease. Insulin resistance and resulting hyperglycemia is the main trigger involved in the initiation of diabetic cardiomyopathy. There is a constellation of many pathophysiological events, such as lipotoxicity, oxidative stress, inflammation, inappropriate activation of the renin-angiotensin-aldosterone system, dysfunctional immune modulation promoting increased rate of cardiac cell injury, apoptosis, and necrosis, which ultimately culminates into interstitial fibrosis, cardiac stiffness, diastolic dysfunction, initially, and later systolic dysfunction too. These events finally lead to clinical heart failure of DCM. Herein, The pathophysiology of DCM is briefly discussed. Furthermore, potential therapeutic strategies currently used for DCM are also briefly mentioned.

Keywords: Diabetic cardiomyopathy, pathophysiology, heart failure, hyperglycemia, insulin resistance, diabetes mellitus.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 31 July, 2020
Page: [268 - 281]
Pages: 14
DOI: 10.2174/1871530320666200731174724
Price: $65

Article Metrics

PDF: 40